# Mass Vaccine and Drug Administration, Bangladesh

> **NCT06068530** · PHASE4 · RECRUITING · sponsor: **University of Oxford** · enrollment: 10000 (estimated)

## Conditions studied

- Plasmodium Falciparum Malaria

## Interventions

- **DRUG:** DHA/piperaquine and a SLD-PQ
- **BIOLOGICAL:** Study vaccine R21/Matrix-M™

## Key facts

- **NCT ID:** NCT06068530
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-15
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068530, "Mass Vaccine and Drug Administration, Bangladesh". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06068530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*